Proteostasis Therapeutics: Investment Landscape Analysis

Proteostasis Therapeutics: Investment Landscape Analysis

Overview

Proteostasis Therapeutics: Investment Landscape Analysis

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Proteostasis Therapeutics: Investment Landscape Analysis</th>
</tr>
<tr>
<td class="label">Phase</td>
<td>Number of Trials</td>
</tr>
<tr>
<td class="label">Phase 1</td>
<td>12</td>
</tr>
<tr>
<td class="label">Phase 2</td>
<td>28</td>
</tr>
<tr>
<td class="label">Phase 3</td>
<td>8</td>
</tr>
<tr>
<td class="label">Completed/Active</td>
<td>7</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Everolimus</td>
<td>Novartis</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Trehalose</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Metformin</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Sodium Phenylbutyrate/Taurursodiol (AMX0035)</td>
<td>Amylyx</td>
</tr>
<tr>
<td class="label">Valproic Acid</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Nicotinamide Riboside</td>
<td>ChromaDex</td>
</tr>
<tr>
<td class="label">NMN</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">HSP90 Imaging</td>
<td>KU Leuven</td>
</tr>
</table>

Proteostasis Therapeutics: Investment Landscape Analysis is a therapeutic approach or intervention being investigated for neurodegenerative diseases. This page reviews the scientific rationale, preclinical and clinical evidence, dosing considerations, and current status of research.

Proteostasis (protein homeostasis) is a fundamental cellular process that maintains protein folding, assembly, and degradation. Dysregulation of proteostasis is a hallmark of neurodegenerative diseases, making proteostasis modulators a promising therapeutic approach.[@hippelainen2023]

Executive Summary

The proteostasis therapeutics field encompasses multiple mechanisms including molecular chaperones, [autophagy](/entities/autophagy) inducers, [HDAC](/entities/hdac-enzymes) inhibitors, and NAD+ boosters. Current clinical trial data shows approximately 130 trials targeting proteostasis pathways in neurodegenerative diseases, representing a growing but still underserved investment area.[@clinicaltrialsgov2026]

Pipeline Overview

Mechanism Breakdown

1. mTOR Inhibitors (81 trials)

[mTOR](/mechanisms/mtor-signaling-pathway-pathway) inhibition induces autophagy, a key protein clearance pathway:

Key Sponsors: Great Lakes NeuroTechnologies Inc., University Hospital Montpellier, University of Minnesota

2. Autophagy Inducers (17 trials)

Direct autophagy enhancement:

Key Sponsors: Columbia University, Seelos Therapeutics

3. HDAC Inhibitors (14 trials)

Histone deacetylase inhibitors modulate proteostasis gene expression:

Key Sponsors: Amylyx Pharmaceuticals Inc., Université de Sherbrooke

4. NAD+ Boosters (11 trials)

NAD+ replenishment supports sirtuin activity and cellular stress resistance:

Key Sponsors: Haukeland University Hospital, McLean Hospital, UC Irvine

5. Lithium (15 trials)

Mood stabilizer with autophagy-inducing properties:

Key Sponsors: SUNY Buffalo, Johns Hopkins

6. Molecular Chaperones (1 trial)

Heat shock protein modulation:

Key Sponsors: Universitaire Ziekenhuizen KU Leuven

Gap Analysis

Underfunded Areas

Investment Opportunities

• HSP90 inhibitors for neuroprotection
• Combined autophagy-lysosome modulators
• Protein folding correctors
• ER stress/UPR modulators
• Multi-target proteostasis modulators

Cross-links to Mechanism Pages

• [Autophagy Pathway](/mechanisms/autophagy)
• [ER Stress Pathway](/mechanisms/er-stress-neurodegeneration)
• [Protein Aggregation](/mechanisms/protein-aggregation)
• [Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome-dysfunction)
• [Mitochondrial Dynamics](/mechanisms/mitochondrial-dynamics-pathway)

See Also

• [Proteostasis](/mechanisms/proteostasis) - Cellular protein quality control
• [Unfolded Protein Response](/mechanisms/er-stress-unfolded-protein-response) - ER stress pathway
• [Parkinson's Disease](/diseases/parkinsons-disease) - Disease context

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
• [Chaperone-Mediated APOE4 Refolding Enhancement](/hypothesis/h-637a53c9) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: HSPA1A, HSP90AA1, DNAJB1, FKBP5
• [Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: PIEZO1 and KCNK2
• [Lipid Droplet Dynamics as Phenotype Switches](/hypothesis/h-7d4a24d3) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: DGAT1 and SOAT1
• [Circadian-Gated Maresin Biosynthesis Amplification](/hypothesis/h-83efeed6) — <span style="color:#81c784;font-weight:600">0.60</span> · Target: ALOX12
• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1

Related Analyses:

• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) &#x1f504;
• [Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving Proteostasis Therapeutics: Investment Landscape Analysis discovered through SciDEX knowledge graph analysis: